GLP-1 signaling is required for improvement of glucose tolerance by osteocalcin

in Journal of Endocrinology
View More View Less
  • 1 OBT Research Center, Faculty of Dental Science, Kyushu University, Fukuoka, Japan
  • 2 Laboratory of Molecular and Cellular Biochemistry, Faculty of Dental Science, Kyushu University, Fukuoka, Japan
  • 3 Department of Immunological and Molecular Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan
  • 4 Division of Functional Structure, Department of Morphological Biology, School of Dental Medicine, Fukuoka Dental College, Fukuoka, Japan
  • 5 Division of Applied Pharmacology, Kyushu Dental University, Kitakyushu, Japan
  • 6 Oral Medicine Research Center, School of Dental Medicine, Fukuoka Dental College, Fukuoka, Japan

Correspondence should be addressed to A Mizokami or M Hirata: or
Restricted access

Osteocalcin is a bone-derived hormone that in its uncarboxylated form (GluOC) plays an important role in glucose and energy metabolism by stimulating insulin secretion and pancreatic β-cell proliferation through its putative receptor GPRC6A. We previously showed that the effect of GluOC on insulin secretion is mediated predominantly by glucagon-like peptide-1 (GLP-1) released from intestinal endocrine cells in response to GluOC stimulation. Moreover, oral administration of GluOC was found to reduce the fasting blood glucose level, to improve glucose tolerance, and to increase the fasting serum insulin concentration and β-cell area in the pancreas in wild-type mice. We have now examined the effects of oral GluOC administration for at least 4 weeks in GLP-1 receptor-knockout mice. Such administration of GluOC in the mutant mice triggered glucose intolerance, enhanced gluconeogenesis and promoted both lipid accumulation in the liver as well as adipocyte hypertrophy and inflammation in adipose tissue. Furthermore, inactivation of GLP-1 receptor signaling in association with GluOC administration induced activation of the transcription factor FoxO1 and expression of its transcriptional coactivator PGC1α in the liver, likely accounting for the observed upregulation of gluconeogenic gene expression. Our results thus indicate that the beneficial metabolic effects of GluOC are dependent on GLP-1 receptor signaling.

Supplementary Materials

    • Supplementary Figure 1. Daily intraperitoneal injection of GluOC induces glucose intolerance in GLP-1R KO mice. Female WT (A) or GLP-1R KO (B) mice at 8 weeks of age were fed a normal diet and subjected to daily (except for Sundays) intraperitoneal injection of either saline (control) or GluOC (10 &#x00B5;g/kg) for 4 weeks. The mice were then subjected to an intraperitoneal GTT. Data are means &#x00B1; SEM for eight to 10 mice per group. *P < 0.05 versus the corresponding value for saline (control) as determined by two-way ANOVA followed by Bonferroni&#x2019;s post hoc test.
    • Supplementary Figure 2. Absorption of GluOC after oral administration in GLP-1R KO mice. The increase in the serum concentration of GluOC (&#x0394;GluOC) in female mice at 8 weeks of age was determined at 3 or 6 h after oral administration of 200 ng (A) or 20 &#x00B5;g (B) of GluOC (closed circles) or saline (open circles). Bars indicate mean values. Serum concentration of GluOC was measured with the use of an enzyme-linked immunoassay (EIA) kit for mouse GluOC (Takara Bio, Shiga, Japan).
    • Supplementary Table 1. Primer sequences for gene expression analysis. Sequences of PCR primers (F, forward; R, reverse) with PrimerBank IDs were obtained from PrimerBank (


      Society for Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 1269 1269 79
Full Text Views 92 92 6
PDF Downloads 53 53 4